comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 03:43:46 - browse：23

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： NYU radiologists take on the challenge of expensive MRI machines

knowledge

WSS

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Gain of function research would be limited under House proposal

DIEP, the 'gold standard' of breast reconstruction, is under threat

Anthos stroke drug appears safer than common blood thinner

Weight loss drug costs may need more research, senator suggests

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

knowledge

Peter Hotez and the public health issue of online harassment

Weight loss drug costs may need more research, senator suggests

Jerome Adams on the need for new antivirals for Covid

After affirmative action ruling, medical educators look to 'holistic review'

Affirmative action in medical school literally saved lives

Ransomware attacks on hospitals: Study outlines patient impact

In Memoriam: Notable people who died in 2023

Congress must reauthorize a committee to support older Americans

In age of alternative facts, a scholarly course on calling out crap

How one medical school became remarkably diverse

knowledge

World's first CRISPR

NYU radiologists take on the challenge of expensive MRI machines

Trump demands the U.S. pay no more for drugs than other countries … again

Hospitals look to new technology to keep health care workers safe

Novavax promises a turnaround & Lilly roils the obesity market

Morphosys mixed study results for blood cancer drug

leisure time

knowledge

knowledge

hotspot